Literature DB >> 20797574

The high prevalence of alexithymia in hemodialyzed patients with secondary hyperparathyroidism unsuppressed by medical therapy is cured by parathyroidectomy.

Rosa Maria De Santo1, Antonio Livrea, Natale G De Santo, Giovanni Conzo, Giancarlo Bilancio, Salvatore Celsi, Massimo Cirillo.   

Abstract

There are scanty data available on alexithymia in patients with end-stage renal disease, which point to an independent association with depression and social support. This study was devised to investigate the prevalence of alexithymia and sleep disorders in patients maintenance hemodialysis with insuppressible secondary hyperparathyroidism, who need parathyroidectomy (PTX), because previous data from our laboratories as well as those of others showed that this patient-group are the worst sleepers among hemodialysis patients with end-stage renal disease. A total of 40 patients needing PTX were enrolled and studied before the surgery. As for the control group, 80 patients on maintenance hemodialysis not needing PTX were enrolled. We measured alexithymia with the Toronto Alexithymia Score (TAS-20), sleep disorders with the Pittsburgh Sleep Quality Index (PSQI), and depression with Beck Depression Inventory (BDI), intact parathyroid hormone (iPTH), calcium, phosphate, use of antihypertensives, systolic and diastolic blood pressure, hemoglobin concentration, and albumin concentration. Patients needing PTX in comparison with those not needing PTX had significantly higher iPTH, calcium, and phosphate; they also had significantly higher systolic and diastolic blood pressure. They were more significantly alexithymic (P < .001), had more severe sleep disorders (P < .001), and were more depressed (P < .043). In multivariate analysis, BDI correlated significantly with iPTH concentration (r = 0.505, P < .001). A reduction of TAS-20 occurred after PTX which correlated with the number of patients on antihypertensive drugs, PSQI, BDI, hemoglobin concentration in the univariate and multivariate analysis. When TAS-20 and PSQI were adjusted for BDI (using analysis of variance) there was still a significant difference of TAS-20 and PSQI between patients needing PTX and not needing PTX (P < .001). This study confirms the high prevalence of sleep disorders in patients with unsuppressed secondary hyperparathyroidism and discloses a high prevalence of Alexithymia which is ameliorated by PTX. However, the correlation of Alexithymia with sleep disorders does not depend on depression. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797574     DOI: 10.1053/j.jrn.2010.06.004

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  4 in total

1.  Alexithymia, Phosphorus Levels, and Sleep Disorders in Patients on Hemodialysis.

Authors:  Đorđe Pojatić; Dajana Nikić; Ivana Tolj; Davorin Pezerović; Andrijana Šantić; Dunja Degmečić
Journal:  J Clin Med       Date:  2022-06-05       Impact factor: 4.964

2.  Real-world evidence and optimization of vocal dysfunction in end-stage renal disease patients with secondary hyperparathyroidism.

Authors:  Geng-He Chang; Fong-Fu Chou; Ming-Shao Tsai; Yao-Te Tsai; Ming-Yu Yang; Ethan I Huang; Hui-Chen Su; Cheng-Ming Hsu
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

3.  Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era.

Authors:  Giovanni Conzo; Alessandra F Perna; Vincenzo Savica; Antonietta Palazzo; Cristina Della Pietra; Diego Ingrosso; Ersilia Satta; Giovambattista Capasso; Luigi Santini; Giovanni Docimo
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

4.  Full normalization of severe hypertension after parathryoidectomy - a case report and systematic review.

Authors:  Andreea Corina Sofronie; Isabelle Kooij; Claude Bursot; Giulia Santagati; Jean-Philippe Coindre; Giorgina Barbara Piccoli
Journal:  BMC Nephrol       Date:  2018-05-11       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.